Publicacións (64) Publicacións nas que participase algún/ha investigador/a

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

  2. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  3. A quantitative method for the detection of muscle functional active and passive behavior recovery in models of damage-regeneration

    Proceedings of the Institution of Mechanical Engineers, Part L: Journal of Materials: Design and Applications, Vol. 233, Núm. 8, pp. 1594-1603

  4. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    Antiviral Therapy, Vol. 24, Núm. 4, pp. 313-319

  5. Analysis of monocitary subpopulations in relation to cardiovascular risk factors

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  6. Anisotropic cryostructured collagen scaffolds for efficient delivery of RhBMP-2 and enhanced bone regeneration

    Materials, Vol. 12, Núm. 19

  7. Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  8. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  9. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

  10. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

    Blood, Vol. 133, Núm. 18, pp. 1953-1963

  11. Circulating microRNAs and their role in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 2

  12. Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

    Cancer, Vol. 125, Núm. 13, pp. 2233-2241

  13. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

  14. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  15. DNA methylation of enhancer elements in myeloid neoplasms: Think outside the promoters?

    Cancers, Vol. 11, Núm. 10

  16. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

  17. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

  18. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  19. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

    Haematologica, Vol. 104, Núm. 8, pp. 1572-1579

  20. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets

    Journal of Immunological Methods, Vol. 475